Orexin receptor antagonists: medicinal chemistry and therapeutic potential.

@article{Roecker2008OrexinRA,
  title={Orexin receptor antagonists: medicinal chemistry and therapeutic potential.},
  author={Anthony J. Roecker and Paul J. Coleman},
  journal={Current topics in medicinal chemistry},
  year={2008},
  volume={8 11},
  pages={
          977-87
        }
}
Actelion Pharmaceuticals achieved clinical proof-of-concept for the treatment of insomnia in 2007 with the release of Phase II data on Almorexant, a potent dual (OX1R/OX2R) orexin receptor antagonist. GlaxoSmithKline also released clinical efficacy data on an orexin receptor antagonist in 2007 for the treatment of insomnia. With these exciting findings, the search for orexin (or hypocretin) receptor antagonists for the treatment of sleep and neurological disorders has recently increased in… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

The DREAM protein is associated with thyroid enlargement and nodular development.

  • Molecular endocrinology
  • 2009
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.

  • The international journal of neuropsychopharmacology
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers

Loading similar papers…